제1장 서 론·················································································1
1. 연구 배경과 목적··································································· 1
2. 연구 범위와 방법··································································· 4
제2장 항노화산업 환경····························································5
1. 산업 개요················································································ 5
2. 산업 성장 동인······································································· 9
1) 과학・기술 측면································································· 9
2) 인구・사회 측면······························································· 12
3. 특화 공공연구기관 사례······················································ 15
1) 해외···················································································· 16
2) 국내···················································································· 27
4. 정책 여건·············································································· 29
1) 정부와 부산시 계획·························································· 29
2) 법률 여건··········································································· 31
5. 부산시 여건·········································································· 34
1) 인구사회············································································· 34
2) 의료산업 기업체 현황······················································ 36
3) 연구개발············································································· 38
4) 관련 공공지원기관···························································· 45
5) 기업체 설문 조사····························································· 48
제3장 국립항노화산업연구원 설립 기본구상······················57
1. 설립의 필요성······································································· 57
2. 임무와 방법·········································································· 62
1) 임무(MISSION) ································································· 62
2) 수행 방법··········································································· 63
3. 조직과 인력·········································································· 67
1) 조직도················································································ 67
2) 부서별 주요 업무····························································· 68
3) 인력 계획··········································································· 73
4. 입지 및 건축········································································ 76
1) 입지···················································································· 76
2) 건축···················································································· 78
참고문헌 ····················································································84
부록 A. 노화종합연구소 필수 장비··········································· 86
부록 B. 기업체 설문지································································ 87
부록 C. 조감도 및 배치도·························································· 94
부록 D. 보건의료 분야 기술성숙도(TRL) 사례······················ 100
<표 Ⅱ-1> 주요 생물학적 노화 이론·············································· 11
<표 Ⅱ-2> 미국 국립노화연구소(NIA) 인력···································· 17
<표 Ⅱ-3> 미국 국립노화연구소(NIA) 연구 방향··························· 21
<표 Ⅱ-4> 일본 국립장수의료연구센터(NCGG) 연구소 인력·········· 25
<표 Ⅱ-5> 국내 항노화 관련 공공 연구기관·································· 27
<표 Ⅱ-6> 2022년 노인인구수 추계 (중위추계) ····························· 36
<표 Ⅱ-7> 부산지역 산업별 사업체수 (2016년) ····························· 37
<표 Ⅱ-8> 부산지역 의료산업관련 학과 현황································ 38
<표 Ⅱ-9> 부산지역 수탁 국가연구과제 건수································ 40
<표 Ⅱ-10> 부산의 의료서비스 전문시설 및 인력 현황················· 41
<표 Ⅱ-11> 종합병원 종사자수 현황 (2016년) ······························· 41
<표 Ⅱ-12> 표본의 분류································································· 49
<표 Ⅱ-13> 기초 통계량································································· 49
<표 Ⅱ-14> 항노화산업 성장과제의 우선순위 ······························ 52
<표 Ⅱ-15> 항노화 특화 공적 연구기관 설립 필요성···················· 52
<표 Ⅱ-16> 항노화산업지원 기능 우선순위···································· 55
<표 Ⅲ-1> 설립 필요성··································································· 57
<표 Ⅲ-2> 부산 설립 필요성·························································· 58
<표 Ⅲ-3> 항노화산업의 대상과 분야, 목표··································· 60
<표 Ⅲ-4> 노화종합연구소 수행 기능 국제 비교··························· 63
<표 Ⅲ-5> 신설 연구기관 경영의 주요 이슈·································· 66
<표 Ⅲ-6> 부서와 임무··································································· 69
<표 Ⅲ-7> 비교 기관의 인력 규모·················································· 74
<표 Ⅲ-8> 소요 인력 계획 (원장 제외) ·········································· 75
<표 Ⅲ-9> 대지 개요······································································ 78
<표 Ⅲ-10> 건축 개요···································································· 79
<표 Ⅲ-11> 층별・동별 면적 규모················································· 79
<표 Ⅲ-12> 국립항노화산업연구원 총사업비 산출························· 82
<표 Ⅲ-13> 연차별 비용 산출························································ 83
<그림 Ⅰ-1> 항노화산업 육성 필요성·············································· 2
<그림 Ⅱ-1> 관리단계에 따른 노화과정··········································· 6
<그림 Ⅱ-2> 항노화산업의 범위······················································· 8
<그림 Ⅱ-3> 주요국의 기대수명 추이············································ 13
<그림 Ⅱ-4> 주요국의 기대수명증가와 합계출산율························ 13
<그림 Ⅱ-5> 국가별 기대수명과 건강수명 증가년수······················ 14
<그림 Ⅱ-6> 미국 국립보건원(NIH) 연구소와 센터························ 16
<그림 Ⅱ-7> 미국 국립노화연구소(NIA) 조직도····························· 17
<그림 Ⅱ-8> 미국 국립노화연구소(NIA) 예산 항목별 지출 비중······· 20
<그림 Ⅱ-9> 일본 국립장수의료연구센터(NCGG) 조직도··············· 23
<그림 Ⅱ-10> NCGG 연구소의 부서와 실험실······························· 24
<그림 Ⅱ-11> 캐나다보건연구원 산하 13개 연구기관···················· 26
<그림 Ⅱ-12> 주요 국가의 노화관련 연구기관 설립 현황············· 28
<그림 Ⅱ-13> 부산과 전국의 노인인구 비중 추이························· 35
<그림 Ⅱ-14> 중입자가속기 치료센터 건물···································· 43
<그림 Ⅱ-15> 항노화산업지원센터 조직도····································· 46
<그림 Ⅱ-16> 매출액 증가율과 특허획득방식································ 50
<그림 Ⅱ-17> 항노화기업의 타지역과의 경쟁력 인식···················· 51
<그림 Ⅱ-18> 공적 항노화연구기관이 필요한 이유························ 53
<그림 Ⅱ-19> 효능 평가, 인증 서비스 이용 의향·························· 54
<그림 Ⅲ-1> 기관의 임무······························································· 62
<그림 Ⅲ-2> 조직도········································································ 67
<그림 Ⅲ-3> CPS, AI 장비 사례···················································· 72
<그림 Ⅲ-4> 대상지 입지 상황······················································· 77
<그림 Ⅲ-5> 국립항노화산업연구원 조감도···································· 80
<그림 Ⅲ-6> 야간 전경··································································· 80
<그림 Ⅲ-7> 전체 배치도······························································· 81
